Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE

Phase 2

• Conditions: Hepatocellular Carcinoma
• Interventions: Device: radiotherapy ablation; Device: transarterial chemoembolization(TACE)

• Registration Number: NCT03642561
• Lead Sponsor: Fudan University

Brief Summary

Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE

Detailed Description

The investigators conduct this clinical trial to evaluate the treatment outcome of RFA in HCC patients with tumor smaller than 7cm and tumor number less than five ,in comparison with TACE treatment.The primary outcome is overall survival.The secondary outcome is objective response rate.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-08-08
• Study First Submitted QC: 2018-08-20
• Study First Posted: 2018-08-22
• Study Start: 2019-09-03
• Status Verified: 2020-07
• Last Update Submitted: 2020-07-25
• Last Update Posted: 2020-07-28
• Primary Completion: 2022-08-01
• Study Completion: 2022-08-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
RFA group	radiotherapy ablation	Patients in RFA group will accept RFA treatment
TACE group	transarterial chemoembolization(TACE)	Patients in TACE group will accept TACE treatment

Primary Outcome Measures

Name	Time	Method
overall survival	up to 60 months

Secondary Outcome Measures

Name	Time	Method
objective response rate	up to 60 months

Trial Locations

Locations (1)

Zhongshan hospital Fudan University; 🇨🇳 Shanghai, China